WallStSmart
PRCT

Procept Biorobotics Corp

NASDAQ: PRCT · HEALTHCARE · MEDICAL DEVICES

$26.45
+3.07% today

Updated 2026-06-05

Market cap
$1.59B
P/E ratio
P/S ratio
4.93x
EPS (TTM)
$-1.83
Dividend yield
52W range
$19 – $67
Volume
1.4M

Procept Biorobotics Corp (PRCT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$6.17M$7.72M$34.47M$75.01M$136.19M$224.50M$308.05M
Revenue growth (YoY)+25.1%+346.7%+117.6%+81.6%+64.8%+37.2%
Cost of revenue$8.05M$8.97M$18.61M$37.93M$65.14M$87.40M$111.83M
Gross profit$-1.89M$-1.25M$15.87M$37.09M$71.05M$137.10M$196.23M
Gross margin-30.6%-16.3%46.0%49.4%52.2%61.1%63.7%
R&D$13.15M$16.27M$18.99M$28.98M$48.45M$62.30M$71.28M
SG&A$28.52M$30.27M$51.04M$88.83M$121.49M$171.41M$228.81M
Operating income$-43.55M$-47.80M$-54.16M$-80.72M$-109.17M$-96.61M$-103.86M
Operating margin-705.9%-619.4%-157.1%-107.6%-80.2%-43.0%-33.7%
EBITDA$-39.76M$-44.90M$-50.72M$-79.13M$-98.09M$-82.00M$-97.47M
EBITDA margin-644.5%-581.8%-147.1%-105.5%-72.0%-36.5%-31.6%
EBIT$-41.25M$-47.76M$-54.04M$-81.97M$-101.90M$-87.23M$-103.86M
Interest expense$724000.00$5.26M$5.81M$5.18M$4.00M$4.18M$3.59M
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-41.98M$-53.02M$-59.85M$-87.15M$-105.90M$-91.41M$-95.57M
Net income growth (YoY)-26.3%-12.9%-45.6%-21.5%+13.7%-4.5%
Profit margin-680.4%-687.0%-173.6%-116.2%-77.8%-40.7%-31.0%

Frequently asked questions

What is Procept Biorobotics Corp's revenue?

Procept Biorobotics Corp's trailing twelve-month revenue is $322.02M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is PRCT?

In its most recent fiscal year, PRCT ran a gross margin of 63.70%, an operating margin of -33.71%, and a net margin of -31.02%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does PRCT generate?

PRCT produced $-58.34M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is PRCT's balance sheet healthy?

PRCT holds $286.50M in cash and equivalents against $51.62M in long-term debt, on $365.87M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.